List of Avycaz drug patents
Avycaz is owned by Allergan.
Avycaz contains Avibactam Sodium; Ceftazidime.
Avycaz has a total of 7 drug patents out of which 0 drug patents have expired.
Avycaz was authorised for market use on 25 February, 2015.
Avycaz is available in powder;intravenous dosage forms.
Avycaz can be used as a method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally effective amount of avibactam sodium; a method of treating bacterial infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pnenumonia (habp/vabp) patients comprising administering a bactericidally effective amount of avibactam sodium; method of treating bacterial infections.
Drug patent challenges can be filed against Avycaz from February, 2024.
The generics of Avycaz are possible to be released after 15 June, 2032.
| Patent Number | Company | Patent Title | Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These patents protects the active chemical substance. Only patent owner can launch products that use this active substance. | ||||
| US7112592 | ALLERGAN | Azabicyclic compounds, preparation thereof and use as medicines, in particular as antibacterial agents |
Jan, 2026
(2 years from now) | |
| US8471025 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Aug, 2031
(8 years from now) | |
| US9695122 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US9284314 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| US8969566 | ALLERGAN | Processes for preparing heterocyclic compounds including trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide and salts thereof |
Jun, 2032
(9 years from now) | |
| These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7612087 | ALLERGAN | Heterocyclic compounds as inhibitors of beta-lactamases |
Nov, 2026
(3 years from now) | |
| US8835455 | ALLERGAN | Crystalline forms of trans-7-oxo-6-(sulphooxy)-1,6-diazabicyclo[3,2,1]octane-2-carboxamide sodium salt |
Oct, 2030
(7 years from now) | |
| Exclusivity | Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity (NCE) | Feb 25, 2020 |
| Generating Antibiotic Incentives Now (GAIN) | Feb 25, 2025 |
Drugs and Companies using AVIBACTAM SODIUM; CEFTAZIDIME ingredient
NCE-1 date: February, 2024
Market Authorisation Date: 25 February, 2015
Treatment: A method of treating bacterial infections in complicated intra-abdominal infection and complicated urinary tract infection, including pyelonephritis, patients comprising administering a bactericidally effective amount of avibactam sodium; A method of treating bacterial infections in hospital-acquired bacterial pneumonia and ventilator-associated bacterial pnenumonia (habp/vabp) patients comprising administering a bactericidally effective amount of avibactam sodium; Method of treating bacterial infections
Dosage: POWDER;INTRAVENOUS
availability in other generic markets.
Click on the highlighted region to filter.
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic